57 results
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
3 Jun 24
Regulation FD Disclosure
4:35pm
treatment, are key goals of the paltusotine development program.”
Long-Term Safety and Efficacy of Once-Daily Oral Paltusotine in the Treatment … who are not candidates for surgery, or when surgery is unsuccessful in achieving treatment goals. Approximately 50% of patients with acromegaly prove
8-K
EX-99.3
CRNX
Crinetics Pharmaceuticals Inc
3 Jun 24
Regulation FD Disclosure
4:35pm
Skillfully Crafted to Help Subjects Reach Their Treatment Goals Stress Hypothalamus Lead Indication: Congenital Adrenal Hyperplasia (CAH) Circadian … Estimated ~27,000 people in the US based on genetic prevalence CRF CRF Clock AVP AVP Treatment Goals Glucocorticoids Normalize/eliminate adrenal androgen
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
surgery is unsuccessful in achieving treatment goals. Approximately 50% of patients with acromegaly prove to be candidates for pharmacotherapy
8-K
EX-99.1
7299tidrrksy6jt1rbdh
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.2
11bkqzxhp p1rc
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-99.1
vh1g iply6crfqg56
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
EX-99.1
b9wq31xesa786a35
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am
8-K
EX-99.1
2yw85lax3o
25 May 22
Regulation FD Disclosure
7:02am